臨床化学分析装置市場：製品別（全自動分析装置、POC分析装置、試薬）、検査タイプ別（基礎代謝、肝臓、腎臓、脂質、甲状腺機能）、エンドユーザー別（病院、診療所、研究所、研究機関）、地域別 - 2028年までの世界予測

Clinical Chemistry Analyzers Market by Product (Fully-automated and PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) & Region - Global Forecast to 2028

臨床化学分析装置の世界市場規模は、2023年の130億米ドルから2028年には165億米ドルに達すると予測され、予測期間中の年平均成長率は4.9%である。臨床化学分析装置市場は、さまざまな要因によって成長を遂げてい... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年7月11日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	185	161	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

臨床化学分析装置の世界市場規模は、2023年の130億米ドルから2028年には165億米ドルに達すると予測され、予測期間中の年平均成長率は4.9%である。臨床化学分析装置市場は、さまざまな要因によって成長を遂げている。主な推進要因としては、高齢者人口の増加、慢性疾患や生活習慣病の有病率の上昇などが挙げられる。また、POC検査機器の採用や検査室自動化需要の高まりも市場拡大に寄与している。しかし、高い設備投資の必要性、熟練した臨床検査技師の不足、再生品の存在といった課題によって、市場の成長は抑制される可能性がある。これらの要因により、当面の市場成長は緩やかになると予想される。
「予測期間中、臨床化学分析装置市場の製品別成長率は試薬が最も高かった。
臨床化学分析装置市場では、分析装置、試薬、その他の製品がセグメントに含まれる。2022年に最も高い成長率を示したのは試薬部門であった。この成長は、分析装置に比べ大量に必要とされる試薬の大幅な需要に起因している。試薬の継続的なニーズと繰り返し購入が、このセグメントの著しい市場成長に寄与している。
「脂質プロファイル検査分野が最も高いCAGRを占める
臨床化学分析装置市場は、基礎代謝パネル、電解質パネル、肝臓パネル、脂質プロファイル、腎臓プロファイル、甲状腺機能パネル、特殊化学検査を含む検査タイプに基づいて分類される。2022年には、脂質プロファイル検査分野が最も高い成長率を示した。このセグメントの成長は、世界的な肥満率の上昇とそれに伴う肥満関連疾患の増加に起因している。このような要因が脂質プロファイル検査の需要を大きく押し上げ、臨床化学分析装置市場における同分野の堅調な成長に寄与している。
「CAGRが最も高いのは病院と診療所である。
臨床化学分析装置市場は、病院・診療所、診断ラボ、研究所・研究機関、その他のエンドユーザーによって区分される。2022年には、病院・診療所が最も高い成長率を示した。この成長の背景には、病気や障害の増加による病院数の世界的な増加などがある。さらに、病院や診療所での分析装置の導入が進んでいることや技術の進歩も、臨床化学分析装置市場における同分野の著しい成長に寄与している。
「アジア太平洋地域：最も急成長している地域の臨床化学分析装置市場"
世界の臨床化学分析装置市場は、北米、欧州、アジア太平洋、中南米、中東・アフリカの各地域に分けられる。なかでも、アジア太平洋地域は予測期間中に最も高い年平均成長率（CAGR）を示すと予測されている。この地域の成長は、主に中国や日本などの国々が牽引している。
アジア太平洋地域における臨床化学分析装置市場の成長にはいくつかの要因が寄与している。第一に、高齢者人口の増加と慢性疾患の負担増が、高度な診断ソリューションに対する大きな需要を生み出している。次に、一人当たり所得の増加と医療インフラの整備が臨床化学分析装置の採用を後押ししている。
さらに、主要な市場関係者はヘルスケア産業に多額の投資を行っており、これが市場の成長をさらに後押ししている。最先端技術に対する需要の高まりや、アジア太平洋地域の各国における民間病院の農村部への進出も市場拡大に寄与している。さらに、同地域では病院や診療所の数が増加しており、医療ニーズの高まりが臨床化学分析装置の需要増につながっている。

本レポートのために実施した一次インタビューは以下のように分類できる：

- 企業タイプ別企業タイプ別：Tier 1 - 40%、Tier 2 - 30%、Tier 3 - 30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米51％、欧州21％、アジア太平洋地域18％、中南米6％、中東・アフリカ4

主要企業は、F.ホフマン・ラ・ロシュ社（スイス）、ダナハー社（スイス）、エフ・ホフマン・ラ・ロシュ社（スイス）である。(スイス）、Danaher Corporation（米国）、Abbott Laboratories（米国）、Thermo Fisher Scientific Inc.(日本）、シスメックス株式会社（日本）、HITACHI（日本）、EKF Diagnostics（英国）、Ortho Clinical Diagnostics（米国）、ELITech Group（フランス）、Mindray Medical International Ltd. （中国）、BIOBASE Inc.(中国）、BIOBASE Group（中国）、SFRI Medical Diagnostics（フランス）、Trivitron Healthcare Pvt.(Ltd.（インド）、Randox Laboratories Ltd.(英国）、Medica Corporation（米国）、Meril Life Sciences Pvt.(Ltd.（インド）、Erba Mannheim（英国）、Genrui Biotech Inc.（中国）、DIRUI Industrial Co.Ltd.（中国）、DIRUI Industrial Co.(中国）、Teco Diagnostics（米国）、Balio Diagnostics（フランス）、Snibe Co.Ltd.（中国(Ltd.（中国）、AMS Alliance（イタリア）。

調査範囲
この調査レポートは、臨床化学分析装置市場を製品、検査タイプ、エンドユーザー、地域別に分類しています。臨床化学分析装置市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、協定、新製品・サービスの発表、M&A、臨床化学分析装置市場に関連する最近の動向などに関する洞察を提供しています。臨床化学分析装置市場のエコシステムにおける今後の新興企業の競争分析もカバーしています。
レポート購入の主な利点
本レポートは、臨床化学分析装置市場全体とそのサブセグメントについて、最も近似した収益数値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートにより、関係者は市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を得ることができます。
本レポートは、以下のポイントに関する洞察を提供します：
- 臨床化学分析装置市場の成長に影響を与える主要な促進要因、阻害要因、機会、課題の分析
- 製品開発/イノベーション：臨床化学分析装置市場における今後の技術、研究開発活動、新製品・サービス開始に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域の臨床化学分析装置市場を分析しています。
- 市場の多様化：臨床化学分析装置市場における新製品・サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競争力の評価：(ホフマン・ラ・ロシュ社（スイス）、ダナハー社（米国）、アボット・ラボラトリーズ社（米国）、サーモフィッシャーサイエンティフィック社（米国）、シーメンス社（ドイツ）など、臨床化学分析装置市場戦略における主要企業の市場ランキング、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.2.2 MARKETS COVERED 26
FIGURE 1 CLINICAL CHEMISTRY ANALYZERS MARKET SEGMENTATION 26
1.2.3 GEOGRAPHIC SCOPE 26
1.2.4 YEARS CONSIDERED 27
1.3 CURRENCY 27
1.4 LIMITATIONS 27
1.5 STAKEHOLDERS 28
1.6 SUMMARY OF CHANGES 28
1.6.1 RECESSION IMPACT 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.2 RESEARCH APPROACH 29
FIGURE 2 CLINICAL CHEMISTRY ANALYZERS MARKET: RESEARCH DESIGN METHODOLOGY 29
2.2.1 SECONDARY DATA 29
2.2.1.1 Key data from secondary sources 30
2.2.2 PRIMARY DATA 31
2.2.2.1 Primary sources 31
2.2.2.2 Key data from primary sources 32
2.2.2.3 Key industry insights 33
2.2.2.4 Breakdown of primary interviews 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 34
2.3 MARKET SIZE ESTIMATION 34
2.3.1 BOTTOM-UP APPROACH 35
2.3.1.1 Approach 1: Company revenue estimation approach 35
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 35
2.3.1.2 Approach 2: Presentations of companies and primary interviews 35
2.3.1.3 Growth forecast 36
2.3.1.4 CAGR projections 36
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 36
2.3.2 TOP-DOWN APPROACH 37
FIGURE 7 CLINICAL CHEMISTRY ANALYZERS MARKET: TOP-DOWN APPROACH 37
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 38
FIGURE 8 DATA TRIANGULATION METHODOLOGY 38
2.5 MARKET SHARE ANALYSIS 39
2.6 STUDY ASSUMPTIONS 39
2.7 RISK ASSESSMENT 39
TABLE 1 CLINICAL CHEMISTRY ANALYZERS MARKET: RISK ASSESSMENT 39
2.8 LIMITATIONS 40
2.9 CLINICAL CHEMISTRY ANALYZERS MARKET: RECESSION IMPACT 40
3 EXECUTIVE SUMMARY 42
FIGURE 9 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 42
FIGURE 10 CLINICAL CHEMISTRY ANALYZERS MARKET, BY ANALYZER TYPE, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION) 43
FIGURE 12 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 44
FIGURE 13 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 45
4 PREMIUM INSIGHTS 46
4.1 CLINICAL CHEMISTRY ANALYZERS MARKET OVERVIEW 46
FIGURE 14 RISING ADOPTION OF POC PRODUCTS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD 46
4.2 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2023 VS. 2028 46
FIGURE 15 REAGENTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 46
4.3 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2023 VS. 2028 47
FIGURE 16 BASIC METABOLIC PANEL SEGMENT TO HOLD LARGEST SHARE DURING FORECAST PERIOD 47
4.4 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2023 VS. 2028 47
FIGURE 17 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 47
4.5 CLINICAL CHEMISTRY ANALYZERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
FIGURE 18 ASIA PACIFIC MARKET EXPECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
FIGURE 19 CLINICAL CHEMISTRY ANALYZERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
5.2.1 DRIVERS 50
5.2.1.1 Rising geriatric population and increasing prevalence of chronic & lifestyle diseases 50
TABLE 2 PERCENTAGE OF POPULATION AGED 65 YEARS OR ABOVE, BY REGION (2022–2050) 50
5.2.1.2 Growing adoption of point-of-care testing devices 51
5.2.1.3 Increasing demand for laboratory automation 52
5.2.2 RESTRAINTS 52
5.2.2.1 Requirement for high capital investments and shortage of skilled laboratory technicians 52
5.2.2.2 Availability of refurbished analyzers 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Increasing government initiatives and funding for preventive care 53
5.2.3.2 Growth opportunities in emerging economies 53
5.2.4 CHALLENGES 54
5.2.4.1 Increasing regulatory requirements 54
5.2.4.2 High degree of consolidation 55
5.3 PRICING ANALYSIS 55
TABLE 3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 55
5.4 PATENT ANALYSIS 57
FIGURE 20 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS (JANUARY 2013–DECEMBER 2022) 57
5.5 VALUE CHAIN ANALYSIS 57
FIGURE 21 VALUE CHAIN ANALYSIS OF CLINICAL CHEMISTRY ANALYZERS MARKET 58
5.6 SUPPLY CHAIN ANALYSIS 59
FIGURE 22 CLINICAL CHEMISTRY ANALYZERS MARKET: SUPPLY CHAIN ANALYSIS 59
5.7 ECOSYSTEM ANALYSIS 60
FIGURE 23 CLINICAL CHEMISTRY ANALYZERS MARKET: ECOSYSTEM ANALYSIS 60
5.8 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 4 CLINICAL CHEMISTRY ANALYZERS MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.8.1 THREAT OF NEW ENTRANTS 61
5.8.2 THREAT OF SUBSTITUTES 61
5.8.3 BARGAINING POWER OF SUPPLIERS 61
5.8.4 BARGAINING POWER OF BUYERS 61
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.9 PESTLE ANALYSIS 62
5.10 REGULATORY ANALYSIS 62
5.10.1 NORTH AMERICA 63
5.10.1.1 US 63
5.10.1.2 Canada 63
5.10.2 EUROPE 63
5.10.3 ASIA PACIFIC 63
5.10.3.1 China 63
5.10.3.2 Japan 63
5.10.3.3 India 64
5.10.4 LATIN AMERICA 64
5.10.4.1 Brazil 64
5.10.4.2 Mexico 64
5.10.5 MIDDLE EAST 65
5.10.6 AFRICA 65
5.11 TRADE ANALYSIS 65
TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 65
TABLE 6 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 66
6 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT 67
6.1 INTRODUCTION 68
TABLE 7 CLINICAL CHEMISTRY REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 68
6.2 REAGENTS 68
6.2.1 RECURRENT PURCHASE REQUIREMENT OF REAGENTS TO DRIVE MARKET 68
TABLE 8 KEY PRODUCTS IN CLINICAL CHEMISTRY ANALYZERS REAGENTS MARKET 68
TABLE 9 CLINICAL CHEMISTRY REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 69
6.3 ANALYZERS 69
TABLE 10 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 70
TABLE 11 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION) 70
6.3.1 SEMI-AUTOMATIC ANALYZERS 70
6.3.1.1 Cost-effectiveness of semi-automatic analyzers to propel segment growth 70
TABLE 12 KEY PRODUCTS IN SEMI-AUTOMATIC CLINICAL CHEMISTRY ANALYZERS MARKET 71
TABLE 13 SEMI-AUTOMATIC ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.3.2 FULLY AUTOMATIC ANALYZERS 72
6.3.2.1 Rapid sample processing and reduction of turnaround times to boost market 72
TABLE 14 KEY PRODUCTS IN FULLY AUTOMATIC CLINICAL CHEMISTRY ANALYZERS MARKET 72
TABLE 15 FULLY AUTOMATIC ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION) 73
6.3.3 POINT-OF-CARE ANALYZERS 73
6.3.3.1 Increasing adoption of PoC technologies to drive segment growth 73
TABLE 16 KEY PRODUCTS IN POINT-OF-CARE CLINICAL CHEMISTRY ANALYZERS MARKET 73
TABLE 17 POINT-OF-CARE ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION) 74
6.4 OTHER PRODUCTS 74
TABLE 18 CLINICAL CHEMISTRY ANALYZERS FOR OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 74
7 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE 75
7.1 INTRODUCTION 76
TABLE 19 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 76
7.2 BASIC METABOLIC PANEL 76
7.2.1 RISING INCIDENCE OF DIABETES AND OTHER CHRONIC DISEASES TO DRIVE MARKET 76
TABLE 20 CLINICAL CHEMISTRY BASIC METABOLIC PANEL TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
7.3 LIVER PANEL 77
7.3.1 INCREASE IN LIVER-RELATED DISEASES TO DRIVE MARKET 77
TABLE 21 CLINICAL CHEMISTRY LIVER PANEL TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 78
7.4 RENAL PROFILE 78
7.4.1 RISING INCIDENCE OF ESRD PATIENTS TO PROPEL GROWTH OF RENAL PROFILE TESTING MARKET 78
TABLE 22 CLINICAL CHEMISTRY RENAL PROFILE TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
7.5 LIPID PROFILE 79
7.5.1 RAPID RISE IN OBESITY RATES TO PROPEL MARKET GROWTH 79
TABLE 23 CLINICAL CHEMISTRY LIPID PROFILE TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
7.6 THYROID FUNCTION PANEL 80
7.6.1 SPIKE IN INCIDENCE OF THYROID-RELATED DISORDERS TO DRIVE MARKET 80
TABLE 24 CLINICAL CHEMISTRY THYROID FUNCTION PANEL TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 81
7.7 ELECTROLYTE PANEL 81
7.7.1 INCREASING PREVALENCE OF HYPERTENSION AND KIDNEY DISEASES TO DRIVE GROWTH 81
TABLE 25 CLINICAL CHEMISTRY ELECTROLYTE PANEL TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 81
7.8 SPECIALTY CHEMICAL TESTS 82
7.8.1 SPECIALTY CHEMICAL TESTS SEGMENT TO GROW AT LOWEST CAGR DURING FORECAST PERIOD 82
TABLE 26 CLINICAL CHEMISTRY SPECIALTY CHEMICAL TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
8 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER 83
8.1 INTRODUCTION 84
TABLE 27 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 84
8.2 HOSPITALS & CLINICS 84
8.2.1 INCREASE IN DISEASES & DISORDERS TO PROPEL MARKET GROWTH 84
TABLE 28 CLINICAL CHEMISTRY ANALYZERS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 85
8.3 DIAGNOSTIC LABORATORIES 85
8.3.1 RISE IN OUTSOURCING ACTIVITIES TO DIAGNOSTIC LABORATORIES AT REDUCED COSTS TO DRIVE MARKET 85
TABLE 29 CLINICAL CHEMISTRY ANALYZERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 86
8.4 RESEARCH LABORATORIES & INSTITUTES 86
8.4.1 GROWTH IN FUNDING FOR LIFE SCIENCE RESEARCH TO BOOST MARKET 86
TABLE 30 CLINICAL CHEMISTRY ANALYZERS MARKET FOR RESEARCH LABORATORIES & INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 87
8.5 OTHER END USERS 87
TABLE 31 CLINICAL CHEMISTRY ANALYZERS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 87
9 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION 88
9.1 INTRODUCTION 89
TABLE 32 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2021–2028 (USD MILLION) 89
9.2 NORTH AMERICA 89
FIGURE 24 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET SNAPSHOT 90
TABLE 33 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 34 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 91
TABLE 35 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 91
TABLE 36 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 92
TABLE 37 NORTH AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 92
9.2.1 US 92
9.2.1.1 Increasing cases of diabetes & obesity-related diseases to boost market 92
TABLE 38 US: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93
TABLE 39 US: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 93
TABLE 40 US: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 94
TABLE 41 US: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 94
9.2.2 CANADA 94
9.2.2.1 Spike in prevalence of chronic & lifestyle diseases to drive market growth in Canada 94
TABLE 42 CANADA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 95
TABLE 43 CANADA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 95
TABLE 44 CANADA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 96
TABLE 45 CANADA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.3 EUROPE 97
TABLE 46 EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 47 EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97
TABLE 48 EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 98
TABLE 49 EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 98
TABLE 50 EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.3.1 GERMANY 99
9.3.1.1 Increasing healthcare expenditure to drive market growth in Germany 99
TABLE 51 GERMANY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 52 GERMANY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 53 GERMANY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 100
TABLE 54 GERMANY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.3.2 UK 101
9.3.2.1 Growing number of accredited clinical laboratories to propel market growth 101
TABLE 55 UK: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 102
TABLE 56 UK: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 57 UK: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 102
TABLE 58 UK: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.3 FRANCE 103
9.3.3.1 Rising R&D expenditure in France to boost market 103
TABLE 59 FRANCE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 104
TABLE 60 FRANCE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 61 FRANCE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 105
TABLE 62 FRANCE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.3.4 ITALY 106
9.3.4.1 Age-related chronic conditions owing to large geriatric population to drive market growth 106
TABLE 63 ITALY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 106
TABLE 64 ITALY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 65 ITALY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 107
TABLE 66 ITALY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.3.5 SPAIN 108
9.3.5.1 Increasing prevalence of age-associated disorders to drive market growth 108
TABLE 67 SPAIN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
TABLE 68 SPAIN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 69 SPAIN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 109
TABLE 70 SPAIN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.3.6 RUSSIA 110
9.3.6.1 Increasing access to quality healthcare to support market growth in Russia 110
TABLE 71 RUSSIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
TABLE 72 RUSSIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 73 RUSSIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 111
TABLE 74 RUSSIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.3.7 REST OF EUROPE 112
TABLE 75 REST OF EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 112
TABLE 76 REST OF EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 77 REST OF EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 113
TABLE 78 REST OF EUROPE: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.4 ASIA PACIFIC 113
FIGURE 25 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET SNAPSHOT 114
TABLE 79 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 80 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 115
TABLE 81 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 82 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 116
TABLE 83 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.4.1 CHINA 116
9.4.1.1 Increasing awareness of preventive care to drive demand for clinical chemistry analyzers 116
TABLE 84 CHINA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117
TABLE 85 CHINA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 86 CHINA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 118
TABLE 87 CHINA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.4.2 JAPAN 118
9.4.2.1 Favorable regulatory framework to drive market growth in Japan 118
TABLE 88 JAPAN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119
TABLE 89 JAPAN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 90 JAPAN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 120
TABLE 91 JAPAN: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.4.3 INDIA 120
9.4.3.1 Increasing private & public investments to propel market growth 120
TABLE 92 INDIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 93 INDIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 94 INDIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 122
TABLE 95 INDIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.4.4 REST OF ASIA PACIFIC 122
TABLE 96 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 97 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 98 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 124
TABLE 99 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.5 LATIN AMERICA 125
TABLE 100 LATIN AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 101 LATIN AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 102 LATIN AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 126
TABLE 103 LATIN AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.6 MIDDLE EAST & AFRICA 127
TABLE 104 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128
TABLE 105 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 106 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 129
TABLE 107 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10 COMPETITIVE LANDSCAPE 130
10.1 OVERVIEW 130
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 130
10.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS 130
TABLE 108 CLINICAL CHEMISTRY ANALYZERS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 130
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 132
FIGURE 26 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL CHEMISTRY MARKET (2022) 132
10.4 MARKET SHARE ANALYSIS 132
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 132
TABLE 109 CLINICAL CHEMISTRY ANALYZERS MARKET: DEGREE OF COMPETITION 133
10.5 COMPANY EVALUATION QUADRANT 133
10.5.1 LIST OF EVALUATED VENDORS 133
10.5.2 STARS 133
10.5.3 EMERGING LEADERS 134
10.5.4 PERVASIVE PLAYERS 134
10.5.5 PARTICIPANTS 134
FIGURE 28 CLINICAL CHEMISTRY ANALYZERS MARKET: COMPANY EVALUATION MATRIX, 2022 134
10.6 COMPANY EVALUATION QUADRANT FOR START-UPS (2022) 135
10.6.1 PROGRESSIVE COMPANIES 135
10.6.2 STARTING BLOCKS 135
10.6.3 RESPONSIVE COMPANIES 135
10.6.4 DYNAMIC COMPANIES 135
FIGURE 29 CLINICAL CHEMISTRY ANALYZERS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS, 2022 136
10.7 COMPETITIVE SCENARIO 136
10.7.1 PRODUCT LAUNCHES & APPROVALS 136
TABLE 110 KEY PRODUCT LAUNCHES & APPROVALS 136
10.7.2 DEALS 137
TABLE 111 KEY DEALS 137
10.7.3 OTHER DEVELOPMENTS 138
TABLE 112 KEY OTHER DEVELOPMENTS 138
11 COMPANY PROFILES 139
11.1 KEY PLAYERS 139
(Business overview, Products offered, Recent developments, Product launches, MnM view, Key strengths, Strategic choices, and Weaknesses & competitive threats)*
11.1.1 F. HOFFMANN-LA ROCHE LTD. 139
TABLE 113 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 139
FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 140
11.1.2 DANAHER CORPORATION 143
TABLE 114 DANAHER CORPORATION: BUSINESS OVERVIEW 143
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 144
11.1.3 ABBOTT LABORATORIES 146
TABLE 115 ABBOTT LABORATORIES: BUSINESS OVERVIEW 146
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 147
11.1.4 SIEMENS HEALTHCARE GMBH 149
TABLE 116 SIEMENS HEALTHCARE GMBH: BUSINESS OVERVIEW 149
FIGURE 33 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022) 150
11.1.5 THERMO FISHER SCIENTIFIC INC. 153
TABLE 117 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 153
FIGURE 34 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 154
11.1.6 HORIBA, LTD. 156
TABLE 118 HORIBA, LTD.: BUSINESS OVERVIEW 156
FIGURE 35 HORIBA, LTD.: COMPANY SNAPSHOT (2022) 157
11.1.7 SYSMEX CORPORATION 160
TABLE 119 SYSMEX CORPORATION: BUSINESS OVERVIEW 160
FIGURE 36 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 161
11.1.8 EKF DIAGNOSTICS 163
TABLE 120 EKF DIAGNOSTICS: BUSINESS OVERVIEW 163
FIGURE 37 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2022) 164
11.1.9 QUIDELORTHO CORPORATION 166
TABLE 121 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 166
FIGURE 38 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 167
11.1.10 HITACHI LTD. 169
TABLE 122 HITACHI LTD.: BUSINESS OVERVIEW 169
FIGURE 39 HITACHI LTD.: COMPANY SNAPSHOT (2022) 170
11.2 OTHER PLAYERS 171
11.2.1 MINDRAY MEDICAL INTERNATIONAL LTD. 171
11.2.2 ELITECH GROUP 172
11.2.3 BIOBASE GROUP 173
11.2.4 SFRI 173
11.2.5 TRIVITRON HEALTHCARE PVT. LTD. 174
11.2.6 RANDOX LABORATORIES LTD. 175
11.2.7 MEDICA CORPORATION 175
11.2.8 MERIL LIFE SCIENCES PVT. LTD. 176
11.2.9 ERBA MANNHEIM 177
11.2.10 GENRUI BIOTECH CO., LTD. 178
11.2.11 DIRUI 179
11.2.12 TECO DIAGNOSTICS 180
11.2.13 BALIO DIAGNOSTICS 181
11.2.14 SNIBE CO. LTD. 182
11.2.15 AMS ALLIANCE 182
*Details on Business overview, Products offered, Recent developments, Product launches, MnM view, Key strengths, Strategic choices, and Weaknesses & competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 183
12.1 DISCUSSION GUIDE 183
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
12.3 CUSTOMIZATION OPTIONS 188
12.4 RELATED REPORTS 188
12.5 AUTHOR DETAILS 189

ページTOPに戻る

Table of Contents

Summary

The global clinical chemistry analyzers market size is projected to reach USD 16.5 billion by 2028 from USD 13.0 billion in 2023, at a CAGR of 4.9% during the forecast period. The clinical chemistry analyzers market is witnessing growth due to various factors. Key drivers include the increasing geriatric population and the rising prevalence of chronic and lifestyle diseases. Additionally, the adoption of Point-of-Care testing devices and the growing demand for laboratory automation contribute to market expansion. However, market growth may be constrained by challenges such as high capital investment requirements, a shortage of skilled clinical laboratory technicians, and the presence of refurbished products. These factors are anticipated to moderate the market's growth in the foreseeable future.
“The reagents accounted for the highest growth rate in the clinical chemistry analyzers market, by product, during the forecast period”
In the clinical chemistry analyzers market, the segments include analyzers, reagents, and other products. The reagents segment exhibited the highest growth rate in 2022. This growth can be attributed to the substantial demand for reagents, which are required in larger quantities compared to analyzers. The continuous need for reagents and repeat purchases contribute to the significant market growth of this segment.
“Lipid profile tests segment accounted for the highest CAGR”
The clinical chemistry analyzers market is categorized based on test types, including basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal profiles, thyroid function panels, and specialty chemical tests. In 2022, the lipid profile tests segment exhibited the highest growth rate. The growth of this segment can be attributed to the escalating obesity rates globally and the subsequent increase in obesity-related diseases. These factors significantly drive the demand for lipid profile tests, contributing to the robust growth of this segment in the clinical chemistry analyzers market.
“Hospitals and clinics segment accounted for the highest CAGR”
The clinical chemistry analyzers market is segmented based on end-users, including hospitals and clinics, diagnostic laboratories, research laboratories and institutes, and other end users. In 2022, the hospitals and clinics segment exhibited the highest growth rate. This growth can be attributed to several factors, such as the global increase in the number of hospitals due to the rising incidences of diseases and disorders. Additionally, the growing adoption of analyzers in hospital and clinic settings, coupled with advancements in technology, has contributed to the significant growth of this segment in the clinical chemistry analyzers market.
“Asia Pacific: The fastest-growing region clinical chemistry analyzers market”
The global clinical chemistry analyzers market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions. Among these, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. The growth in this region is primarily driven by countries like China and Japan.
Several factors contribute to the growth of the clinical chemistry analyzers market in the Asia Pacific region. Firstly, the rising geriatric population and the increasing burden of chronic diseases create a significant demand for advanced diagnostic solutions. Secondly, the growing per capita income and improving healthcare infrastructure in countries across the region support the adoption of clinical chemistry analyzers.
Moreover, key market players are making substantial investments in the healthcare industry, which further fuels the growth of the market. The increasing demand for cutting-edge technologies and the expansion of private-sector hospitals into rural areas in various countries in the Asia Pacific region also contribute to market expansion. Additionally, the rising number of hospitals and clinics in the region addresses the growing healthcare needs of the population, resulting in increased demand for clinical chemistry analyzers.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18% and Latin America 6% and Middle East & Africa 4%

Prominent companies are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China) and AMS Alliance (Italy).

Research Coverage:
This research report categorizes the clinical chemistry analyzers market by product, test type, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical chemistry analyzers market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical chemistry analyzers market. Competitive analysis of upcoming startups in the clinical chemistry analyzers market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical chemistry analyzers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical chemistry analyzers market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical chemistry analyzers market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the clinical chemistry analyzers market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical chemistry analyzers market.
• Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), among others in the clinical chemistry analyzers market strategies.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（analyzers market）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（analyzers market）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?